MYD88 L265P found in ~5-10% of MZL (more in lymphoplasmacytoid variants; rare in classic...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MYD88-L265P-SPLENIC-MZL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-SPLENIC-MZL |
| Sources | SRC-BSH-MZL-2024 SRC-CIVIC SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-MYD88-L265P |
|---|---|
| Variant | L265P |
| Disease | DIS-SPLENIC-MZL |
| ESCAT tier | IIIA |
| Recommended combinations | ibrutinib (off-label R/R MZL), zanubrutinib (FDA-approved R/R MZL — not MYD88-selected) |
| Evidence summary | MYD88 L265P found in ~5-10% of MZL (more in lymphoplasmacytoid variants; rare in classic SMZL/NMZL). Suggests overlap with WM biology and supports BTKi consideration in R/R disease (off-label). |
Notes
ESCAT IIIA. Zanubrutinib has tissue-agnostic MZL approval (MAGNOLIA) regardless of MYD88 status.
Used By
No reverse references found in the YAML corpus.